Nanopharm Ltd., an Aptar Pharma company and provider of contract research and development of orally inhaled and nasally delivered drug products (OINDP), and Leyden Labs, a company targeting commonalities of viral families to protect humanity from known and future viruses, have entered into an agreement to develop nasal sprays that may provide broad protection against respiratory viruses, combining Leyden Labs’ portfolio and Nanopharm’s expertise in the development of nasally delivered drug produ...